Oncotarget

Research Papers:

Decreased fucosylated PSA as a urinary marker for high Gleason score prostate cancer

Kazutoshi Fujita _, Takuji Hayashi, Kyosuke Matsuzaki, Wataru Nakata, Mika Masuda, Atsunari Kawashima, Takeshi Ujike, Akira Nagahara, Mutsumi Tsuchiya, Yuka Kobayashi, Satoshi Nojima, Motohide Uemura, Eiichi Morii, Eiji Miyoshi and Norio Nonomura

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:56643-56649. https://doi.org/10.18632/oncotarget.10987

Metrics: PDF 1146 views  |   HTML 1216 views  |   ?  


Abstract

Kazutoshi Fujita1, Takuji Hayashi1, Kyosuke Matsuzaki1, Wataru Nakata1, Mika Masuda2, Atsunari Kawashima1, Takeshi Ujike1, Akira Nagahara1, Mutsumi Tsuchiya1, Yuka Kobayashi3, Satoshi Nojima4, Motohide Uemura1, Eiichi Morii4, Eiji Miyoshi2, Norio Nonomura1

1Department of Urology, Osaka University Graduate School of Medicine, Suita, Japan

2Department of Molecular Biochemistry and Clinical Investigation, Osaka University Graduate School of Medicine, Suita, Japan

3J-Oil Mills, Inc., Yokohama, Japan

4Department of Pathology, Osaka University Graduate School of Medicine, Suita, Japan

Correspondence to:

Kazutoshi Fujita, email: kazu.fujita2@gmail.com

Keywords: prostate cancer, fucosylation, PSA, urine, Gleason score

Received: May 30, 2016     Accepted: July 13, 2016     Published: August 01, 2016

ABSTRACT

Fucosylation is an important oligosaccharide modification associated with cancer and inflammation. We investigated whether urinary fucosylated PSA (Fuc-PSA) levels could be used for the detection of high Gleason score prostate cancer. Urine samples were collected from men with abnormal digital rectal examination findings or elevated serum PSA levels, before prostate biopsy. Lectin-antibody ELISA was used to quantify the Lewis-type or core-type fucosylated PSA (PSA-AAL) and core-type fucosylated PSA (PSA-PhoSL) in the urine samples. Both types of urinary Fuc-PSA were significantly decreased in the men with prostate cancer compared with the men whose biopsies were negative for cancer (P = 0.026 and P < 0.001, respectively). Both were also significantly associated with the Gleason scores of the biopsy specimens (P = 0.001 and P < 0.001, respectively). Multivariate analysis showed that PSA density, urinary PSA-AAL, and urinary PSA-PhoSL were independent predictors of high Gleason score prostate cancer. The area under the receiver-operator characteristic curve (AUC) value for the prediction of cancers of Gleason score ≥ 7 was 0.69 for urinary PSA-AAL and 0.72 for urinary PSA-PhoSL. In contrast, the AUC value was 0.59 for serum PSA, 0.63 for PSA density, and 0.58 for urinary PSA. In conclusion, a decreased urinary Fuc-PSA level is a potential marker for the detection of high Gleason score prostate cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 10987